Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2022-06-29
Target enrollment:
Participant gender:
Summary
To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as
28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple
myeloma, to test the 600 mcg/d dose, given as a 28-day continuous iV infusion.